Sorafenib in combination with paclitaxel for locally recurrent or metastatic breast cancer

A novel strategy in treating endocrine resistance using combination therapy

Lapatinib alone or in combination with trastuzumab for HER2+ metastatic breast cancer

Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer

Bevacizumab plus docetaxel compared with placebo plus docetaxel for locally recurrent or metastatic breast cancer

Exemestane vs tamoxifen followed by exemestane

Adult acute lymphoblastic leukaemia

Using biology of tumours to predict effective therapies

Translation of endocrine systemic treatment

T-cell therapies

The International Consortium on Acute Promyelocytic Leukemia

Myeloid supressor cells